PMID- 1974635
OWN - NLM
STAT- MEDLINE
DCOM- 19900917
LR  - 20181130
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 254
IP  - 2
DP  - 1990 Aug
TI  - Serotonin release contributes to the locomotor stimulant effects of 
      3,4-methylenedioxymethamphetamine in rats.
PG  - 456-64
AB  - Methylenedioxymethamphetamine (MDMA) is a phenylethylamine with novel 
      mood-altering properties in humans. MDMA shares the dopamine-releasing properties 
      of amphetamine but has been found to be a more potent releaser of serotonin 
      (5-HT). The present study undertook to determine the relative roles of dopamine 
      and 5-HT release in MDMA-induced locomotor hyperactivity. S-(+)MDMA produced 
      dose-dependent increases of rat locomotion. Investigatory behaviors such as 
      holepokes and rearings were suppressed by (+)MDMA. Pretreatment with the 
      selective 5-HT uptake inhibitors fluoxetine, sertraline and zimelidine inhibited 
      (+)MDMA-induced locomotor hyperactivity but failed to antagonize the reduction of 
      holepokes and rearings. Because 5-HT uptake inhibitors have been found previously 
      to block the MDMA-induced release of 5-HT in vitro, and because fluoxetine was 
      found to have no effect on (+)amphetamine-induced hyperactivity, the present 
      results suggest that (+) MDMA-induced locomotor hyperactivity is dependent on 
      release of endogenous 5-HT. Additionally, prior depletion of central 5-HT with 
      p-chlorophenylalanine partially antagonized the (+)MDMA-induced hyperactivity, 
      although catecholamine synthesis inhibition with alpha-methyl-p-tyrosine did not 
      block the effects of (+)MDMA. Taken together, these studies suggest that (+)MDMA 
      increases locomotor activity via mechanisms that are dependent on the release of 
      central 5-HT and that are qualitatively different from the mechanism of action of 
      (+)amphetamine.
FAU - Callaway, C W
AU  - Callaway CW
AD  - Department of Psychiatry, UCSD School of Medicine, La Jolla.
FAU - Wing, L L
AU  - Wing LL
FAU - Geyer, M A
AU  - Geyer MA
LA  - eng
GR  - DA02925/DA/NIDA NIH HHS/United States
GR  - M-07198/PHS HHS/United States
GR  - MH00188/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Amphetamines)
RN  - 01K63SUP8D (Fluoxetine)
RN  - 333DO1RDJY (Serotonin)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - CK833KGX7E (Amphetamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - R5J7E3L9SP (Fenclonine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/analogs & derivatives/antagonists & 
      inhibitors/*pharmacology
MH  - Amphetamine/pharmacology
MH  - Amphetamines/*pharmacology
MH  - Animals
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Fenclonine/pharmacology
MH  - Fluoxetine/pharmacology
MH  - Gait/*drug effects
MH  - Injections, Subcutaneous
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Serotonin/*metabolism
EDAT- 1990/08/01 00:00
MHDA- 1990/08/01 00:01
CRDT- 1990/08/01 00:00
PHST- 1990/08/01 00:00 [pubmed]
PHST- 1990/08/01 00:01 [medline]
PHST- 1990/08/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1990 Aug;254(2):456-64.